secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261753
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lyell CEO Lynn Seely appointed interim CFO; Veronica Sanchez Bulis named principal accounting officer
--------------------------------------------------------------------------------

- Board appointed CEO Lynn Seely as interim principal financial officer on Oct 31, 2025; also remains CEO and director.
- Veronica Sanchez Bulis, VP Corporate Controller since Aug 2021, appointed principal accounting officer.
- Bulis previously held senior finance roles at Sangamo Therapeutics and Core-Mark International; began career at EY and Deloitte.
- No departure or replacement of a named executive officer was disclosed; changes effective immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525261753/0001193125-25-261753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525261753/d73457d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer